Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorine F 18 sodium fluoride + fludeoxyglucose F-18
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Fluorine F 18 sodium fluoride + fludeoxyglucose F-18 is a dual-tracer radiopharmaceutical combination used for diagnostic imaging via positron emission tomography (PET). Fluorine F 18 sodium fluoride (NaF) acts as a bone-seeking agent, depositing in the hydroxyapatite matrix of bone, particularly in areas of active remodeling such as osteoblastic metastases. Fludeoxyglucose F 18 (FDG) is a glucose analog that is taken up by cells with high metabolic rates, such as malignant tumors, and is trapped intracellularly after phosphorylation. This combination is being investigated by Stanford University in a "one-stop-shop" PET/MRI protocol to evaluate treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC), specifically those receiving radium Ra 223 dichloride (Xofigo), by providing a comprehensive view of both metabolic and structural disease activity.
- Other names
- NaF/FDGFluorine F 18 Sodium Fluoride and Fludeoxyglucose F 18Sodium Fluoride F 18 InjectionFludeoxyglucose F 18 Injection
02
Targets
GLUT (Glucose transporter family)GCK (Glucokinase)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)
Beyond the preview
Go deeper on fluorine F 18 sodium fluoride + fludeoxyglucose F-18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorine F 18 sodium fluoride + fludeoxyglucose F-18.